August 16, 2017

Breaking News: FDA Panel Unanimously Recommends Approval of Dabigatran to Decrease Stroke Risk in Atrial Fibrillation

An FDA panel today unanimously recommended that the FDA approve dabigatran (Pradaxa) for reducing the risk of afib strokes. FDA approval is expected quickly, making this the first alternative to warfarin approved in the United States, and also the first atrial fibrillation approval for dabigatran. It is approved in over 70 countries for venous thromboembolisms (blood clots in a vein), but not for atrial fibrillation.

Find out about advantages of dabigatran for afib:

FDA Panel Votes for Dabigatran: Good News for Atrial Fibrillation Patients

Comments

  1. Ken Sturmer says:

    I second what Wanda said. I currently take aspirin not coumadin, but a 325mg dose daily. From what I read, this drug has much less danger from bleeding than either Coumadin or Aspirin. That would be great news!

  2. THIS WOULD BE WONDERFUL IF THEY APPROVE IT. I PRAY THEY WILL . THANKS FOR THE INFO. WANDA PENGELLY

Comment